Short Interest in TransMedics Group, Inc. (NASDAQ:TMDX) Drops By 13.3%

TransMedics Group, Inc. (NASDAQ:TMDX) saw a large decline in short interest during the month of February. As of February 28th, there was short interest totalling 9,330,000 shares, a decline of 13.3% from the February 13th total of 10,760,000 shares. Based on an average daily volume of 1,880,000 shares, the days-to-cover ratio is currently 5.0 days. Approximately 29.9% of the company’s shares are sold short.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Robert W. Baird decreased their target price on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a report on Wednesday, December 11th. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $75.00 target price (down from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Piper Sandler decreased their price objective on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a report on Wednesday, December 11th. Oppenheimer restated an “outperform” rating and issued a $125.00 price objective on shares of TransMedics Group in a report on Tuesday, December 3rd. Finally, Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a report on Wednesday, February 5th. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $122.70.

TransMedics Group Trading Up 1.9 %

Shares of NASDAQ:TMDX opened at $70.33 on Thursday. TransMedics Group has a 52 week low of $55.00 and a 52 week high of $177.37. The company’s 50 day moving average is $68.19 and its two-hundred day moving average is $91.91. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The company has a market cap of $2.37 billion, a PE ratio of 74.82 and a beta of 2.12.

Institutional Investors Weigh In On TransMedics Group

A number of large investors have recently modified their holdings of the company. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of TransMedics Group in the 4th quarter valued at approximately $4,131,000. Mackenzie Financial Corp increased its position in shares of TransMedics Group by 73.0% in the 4th quarter. Mackenzie Financial Corp now owns 828,147 shares of the company’s stock valued at $51,635,000 after purchasing an additional 349,403 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of TransMedics Group in the 4th quarter valued at approximately $1,436,000. Pacific Point Advisors LLC purchased a new stake in shares of TransMedics Group in the 4th quarter valued at approximately $561,000. Finally, Palisades Investment Partners LLC increased its position in shares of TransMedics Group by 7.6% in the 4th quarter. Palisades Investment Partners LLC now owns 160,108 shares of the company’s stock valued at $9,983,000 after purchasing an additional 11,323 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.